A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Inclusion Criteria: * Patient with AML and \>=18 years of age. * Agrees to participate in the study and signs the informed consent * Viable cells are available for successful modification * First or higher complete remission and have high risk features of relapse. * Patients who have received prior treatment and are not in remission must have stable white blood cell count and are not receiving any chemotherapy or desiring further intensive treatment. * Less than 10% blast cells in the bone marrow following induction or re-induction therapy and not desiring further intensive treatment. * Acceptable creatinine, Aspartate transaminase (AST), Alkaline phosphatase (ALP), bilirubin lab results. * Agree to use contraception * Not pregnant * Able to comply with study procedures Exclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status \>2 * Known persistent infection * Known central nervous system (CNS) disease * Greater than 10% blasts in the bone marrow or circulating blast cells * Life expectancy \< 2 months * Receiving any chemotherapy, corticosteroids, Cox2 inhibitors or any non-drug therapies with the intent of altering the immune response or kill leukemic cells within one week prior to infusion of IL-12, except azacytidine. * Patients who are HIV positive.